Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Canada Holdings, L.P. • Arena Pharmaceuticals Development GmbH ...
PFE stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
14 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
S-3ASR
Automatic shelf registration
23 Feb 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
30 Jan 24
8-K
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
10 Jan 24
8-K/A
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Pfizer Completes Acquisition of Seagen
14 Dec 23
8-K
Full-Year 2024 Revenue Guidance(1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition
13 Dec 23
Transcripts
PFE
Earnings call transcript
2023 Q4
30 Jan 24
PFE
Earnings call transcript
2023 Q3
31 Oct 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q1
2 May 23
PFE
Earnings call transcript
2022 Q4
31 Jan 23
PFE
Earnings call transcript
2022 Q3
1 Nov 22
PFE
Earnings call transcript
2022 Q2
28 Jul 22
PFE
Earnings call transcript
2022 Q1
3 May 22
PFE
Earnings call transcript
2021 Q4
8 Feb 22
PFE
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn |
Cash burn (monthly) | (no burn) | (no burn) | 1.12 bn | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 6.27 bn | n/a | n/a | n/a |
Cash remaining | n/a | n/a | -3.03 bn | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | -2.7 | n/a | n/a | n/a |
Institutional ownership, Q4 2023
48.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2453 |
Opened positions | 241 |
Closed positions | 642 |
Increased positions | 710 |
Reduced positions | 1358 |
13F shares | Current |
---|---|
Total value | 74.73 tn |
Total shares | 2.75 bn |
Total puts | 17.83 mm |
Total calls | 33.89 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 506.52 mm | $14.58 tn |
STT State Street | 287.48 mm | $8.28 tn |
Wellington Management | 239.21 mm | $6.89 tn |
Capital World Investors | 173.39 mm | $4.99 tn |
Charles Schwab Investment Management | 104.25 mm | $2.99 tn |
MS Morgan Stanley | 82.11 mm | $2.36 tn |
Massachusetts Financial Services | 68.51 mm | $1.97 tn |
NTRS Northern Trust | 59.81 mm | $1.72 tn |
LGEN Legal & General | 49.62 mm | $1.43 tn |
BK Bank Of New York Mellon | 44.09 mm | $1.27 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 27.94 | 8 | 223.52 | 659,156 |
15 Mar 24 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 27.94 | 87 | 2.43 k | 27,635 |
4 Mar 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Discretionary | Acquire I | No | No | 25.89 | 88,240 | 2.28 mm | 659,573 |
28 Feb 24 | Mikael Dolsten | Common Stock | Payment of exercise | Dispose F | No | No | 27.04 | 21,437 | 579.66 k | 321,729 |
28 Feb 24 | Christoffel Boshoff | Common Stock | Payment of exercise | Dispose F | No | No | 27.04 | 4,150 | 112.22 k | 156,007 |
28 Feb 24 | Christoffel Boshoff | Common Stock | Grant | Acquire A | No | No | 0 | 11,510 | 0.00 | 160,157 |
News
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
18 Mar 24
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
15 Mar 24
Decoding Pfizer's Options Activity: What's the Big Picture?
15 Mar 24
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
14 Mar 24
How To Earn $500 A Month From Pfizer Stock After A Surprise Profit-Turning Quarter
14 Mar 24
Press releases
European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
13 Mar 24
Thinking about trading options or stock in Apple, Pfizer, Taiwan Semiconductor, Microsoft, or Novo Nordisk?
12 Mar 24
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
12 Mar 24
Thinking about trading options or stock in Advanced Micro Devices, Pfizer, Samsara, New York Community Bancorp, or Walmart?
8 Mar 24
ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
6 Mar 24